ES2550461T3 - Uso de S-adenosilmetionina (SAM) y superóxido dismutasa (SOD) para la preparación de medicamentos para el tratamiento de la enfermedad de Alzheimer - Google Patents

Uso de S-adenosilmetionina (SAM) y superóxido dismutasa (SOD) para la preparación de medicamentos para el tratamiento de la enfermedad de Alzheimer Download PDF

Info

Publication number
ES2550461T3
ES2550461T3 ES09714406.7T ES09714406T ES2550461T3 ES 2550461 T3 ES2550461 T3 ES 2550461T3 ES 09714406 T ES09714406 T ES 09714406T ES 2550461 T3 ES2550461 T3 ES 2550461T3
Authority
ES
Spain
Prior art keywords
adenosylmethionine
sod
sam
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09714406.7T
Other languages
English (en)
Inventor
Sigfrido Scarpa
Andrea Fuso
Rosellina Damiani
Mauro Rossini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gnosis SpA
Original Assignee
Gnosis SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnosis SpA filed Critical Gnosis SpA
Application granted granted Critical
Publication of ES2550461T3 publication Critical patent/ES2550461T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

El uso de S-adenosilmetionina (SAM) en combinación con superóxido dismutasa (SOD) para la preparación de medicamentos para el tratamiento de la enfermedad de Alzheimer.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES09714406.7T 2008-02-29 2009-02-25 Uso de S-adenosilmetionina (SAM) y superóxido dismutasa (SOD) para la preparación de medicamentos para el tratamiento de la enfermedad de Alzheimer Active ES2550461T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425123A EP2095828A1 (en) 2008-02-29 2008-02-29 Use of S-adenosylmethionine (SAM) and superoxide dismutase (SOD) for the preparation of medicaments for the treatment of Alzeimer's disease
EP08425123 2008-02-29
PCT/EP2009/001323 WO2009106302A1 (en) 2008-02-29 2009-02-25 Use of s-adenosylmethionine (sam) and superoxide dismutase (sod) for the preparation of medicaments for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
ES2550461T3 true ES2550461T3 (es) 2015-11-10

Family

ID=39529658

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09714406.7T Active ES2550461T3 (es) 2008-02-29 2009-02-25 Uso de S-adenosilmetionina (SAM) y superóxido dismutasa (SOD) para la preparación de medicamentos para el tratamiento de la enfermedad de Alzheimer

Country Status (25)

Country Link
US (1) US8778337B2 (es)
EP (2) EP2095828A1 (es)
JP (1) JP5362747B2 (es)
KR (1) KR101297763B1 (es)
CN (2) CN104189895B (es)
AU (1) AU2009218723B2 (es)
BR (1) BRPI0908024A2 (es)
CA (1) CA2716893C (es)
CY (1) CY1116782T1 (es)
DK (1) DK2249868T3 (es)
ES (1) ES2550461T3 (es)
GE (1) GEP20125638B (es)
HR (1) HRP20151241T1 (es)
HU (1) HUE028183T2 (es)
IL (1) IL207807A (es)
MX (1) MX2010009384A (es)
NZ (1) NZ587608A (es)
PL (1) PL2249868T3 (es)
PT (1) PT2249868E (es)
RS (1) RS54442B1 (es)
RU (1) RU2472513C2 (es)
SI (1) SI2249868T1 (es)
UA (1) UA97440C2 (es)
WO (1) WO2009106302A1 (es)
ZA (1) ZA201006085B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150064423A (ko) * 2013-12-03 2015-06-11 경상대학교산학협력단 오스모틴을 유효성분으로 함유하는 인지기능 개선용 조성물
KR101689681B1 (ko) * 2016-06-07 2016-12-26 경상대학교산학협력단 오스모틴을 유효성분으로 함유하는 인지기능 개선용 조성물
CN118103053A (zh) 2021-09-30 2024-05-28 韩国韩医学研究院 包含半夏、大枣、甘草、人参、干姜、黄芩和黄连的混合提取物作为活性成分的用于治疗阿尔茨海默病的组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519058A (en) * 1989-03-17 1996-05-21 Cedars-Sinai Medical Center Method for treatment with dimercaptosuccinic acid (DMSA) of hypertension, diabetic neuphropathy and atherosclerosis
CN1099224A (zh) * 1993-08-23 1995-03-01 庭野七郎 人参叶加工的食品及其制造方法
US6096778A (en) * 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US6797289B2 (en) * 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US20020025926A1 (en) * 2000-08-30 2002-02-28 Hebert Rolland F. Enantiomers of S-adenosyl-l-methionine
IT1317920B1 (it) 2000-10-20 2003-07-15 Univ Roma S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer.
US6759395B2 (en) * 2000-12-18 2004-07-06 Orchid Chemicals & Pharmaceuticals, Ltd. Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same
FR2822381B1 (fr) * 2001-03-20 2004-10-22 Bio Obtention Sc Extrait de cucumis melo enrobe et/ou microencapsule dans un agent liposoluble a base de matiere grasse
ITMI20012462A1 (it) * 2001-11-22 2003-05-22 Gnosis Srl Processo per la preparazione di compresse comprendenti s-adenosilmetionina
WO2004034963A2 (en) * 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20070116696A1 (en) * 2003-10-03 2007-05-24 Green Meadows Research, Llc Lotus and methyl donors
ES2406412T3 (es) 2005-06-09 2013-06-06 Gnosis S.P.A. Células de Saccharomyces cerevisiae secas, liofilizadas y/o microencapsuladas con un alto contenido de (S)-(+)-S-adenosil-metionina

Also Published As

Publication number Publication date
SI2249868T1 (sl) 2015-12-31
RU2472513C2 (ru) 2013-01-20
HUE028183T2 (en) 2016-12-28
AU2009218723B2 (en) 2014-01-30
CN104189895A (zh) 2014-12-10
CA2716893A1 (en) 2009-09-03
CN104189895B (zh) 2016-08-31
NZ587608A (en) 2012-07-27
ZA201006085B (en) 2011-10-26
UA97440C2 (en) 2012-02-10
MX2010009384A (es) 2010-12-21
WO2009106302A1 (en) 2009-09-03
PL2249868T3 (pl) 2016-03-31
DK2249868T3 (en) 2015-11-23
EP2249868B1 (en) 2015-09-02
IL207807A0 (en) 2010-12-30
JP2011513257A (ja) 2011-04-28
US20110020301A1 (en) 2011-01-27
KR20100126326A (ko) 2010-12-01
PT2249868E (pt) 2015-11-03
RS54442B1 (sr) 2016-06-30
US8778337B2 (en) 2014-07-15
CY1116782T1 (el) 2017-03-15
EP2249868A1 (en) 2010-11-17
AU2009218723A1 (en) 2009-09-03
CA2716893C (en) 2014-05-20
GEP20125638B (en) 2012-09-10
JP5362747B2 (ja) 2013-12-11
EP2095828A1 (en) 2009-09-02
KR101297763B1 (ko) 2013-08-20
IL207807A (en) 2015-08-31
HRP20151241T1 (hr) 2015-12-18
RU2010135467A (ru) 2012-04-10
CN101965197A (zh) 2011-02-02
BRPI0908024A2 (pt) 2018-11-06

Similar Documents

Publication Publication Date Title
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2496092T3 (es) El uso de amisulprida para tratar náuseas y vómitos posoperatorios
ES2540751T3 (es) Composición para mejorar la función sexual masculina que contiene extracto de baya de ginseng
ES2483725T3 (es) Composición básica cosmética y su uso
ES2552651T3 (es) Composición inyectable de polidesoxirribonucleótido para el tratamiento de enfermedades osteoarticulares
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
DOP2014000260A (es) Compuestos d-aminoácidos para enfermedad hepática
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
ES2494316T3 (es) Ingrediente activo novedoso en cicatrización y uso del mismo
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
DOP2007000102A (es) Arilimidazolonas y ariltriazolona sustituidas asi como su uso
GT200900201A (es) Formulaciones para el tratamiento del cáncer.
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2008000254A1 (es) Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer.
ES2629309T3 (es) Formulaciones de tratamiento de la mucositis inducida por terapia antitumoral o inmunosupresora
ES2496669T3 (es) Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen
BR112013014189A2 (pt) composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2007002769A1 (es) Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes.